Placenta PreviaVEGF PPNCT06620068
Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
An observational study of Placenta Previa, run by Guangzhou Institute of Respiratory Disease.
Trial summary
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Placenta Previa
- How many people
- 207,473 participants
- Where
- No sites listed yet
- Study dates
- 25 Sep 2024to 1 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This study analyzes data from European populations included in genome-wide association studies (GWAS) from UK Biobank and FinnGen, focusing on individuals with available plasma VEGF family protein levels and placenta previa data.
Who may be able to join
- Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.
Who cannot join
- Participants with incomplete or missing data on plasma VEGF levels or placenta previa.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.
Read the detailed description
Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.
- Conditions
- Placenta Previa
- Keywords
- Vascular Endothelial Growth Factor (VEGF), Mendelian Randomization, Angiogenesis, Pregnancy Complications, Placental Development
- Medical subject headings
- Placenta Previa, Pregnancy Complications
What is being measured
The primary outcome is the main question the study is designed to answer.
Causal relationship between plasma VEGFA levels and the risk of placenta previa
This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Measured: Data analysis and outcome assessment will be completed by December 2024
Secondary outcomes (3)
Causal relationship between plasma VEGFB levels and the risk of placenta previa
This outcome measures the association between plasma VEGFB levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Measured: Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma VEGFC levels and the risk of placenta previa
This outcome measures the association between plasma VEGFC levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Measured: Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma PLGF levels and the risk of placenta previa
This outcome measures the association between plasma PLGF levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Measured: Data analysis and outcome assessment will be completed by December 2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start25 Sep 2024 (estimated)
- Primary completion1 Nov 2024 (estimated)
- Study completion1 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Placenta PreviaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 207,473 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guangzhou Institute of Respiratory Disease
- Sponsor type
- University, hospital or other
- Collaborators
- The Second People's Hospital of Foshan, First People's Hospital of Foshan, Maternal and Child Health Hospital of Foshan
- Responsible party
- Principal investigator, Zhibin Xu, Guangzhou Institute of Respiratory Disease
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06620068
- Sponsor's protocol ID
- FSKY20240924
- Acronym
- VEGF PP
- Status last verified
- Sep 2024
- First submitted
- 24 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Hong Z, Xu Z, Huang Z, Li W, Liu Q. Causal association between plasma vascular endothelial growth factor family proteins and placenta previa: A 2-sample Mendelian randomization study. Medicine (Baltimore). 2026 Oct 16;105(42):e51193. doi: 10.1097/MD.0000000000051193.
PubMed 42888602
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
- ClinicalTrials.gov ID
- NCT06620068
- Acronym / sponsor ID
- VEGF PP / FSKY20240924
- Conditions
- Placenta Previa
- Keywords
- Vascular Endothelial Growth Factor (VEGF), Mendelian Randomization, Angiogenesis, Pregnancy Complications, Placental Development
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 207,473 participants (estimated)
- Lead sponsor
- Guangzhou Institute of Respiratory DiseaseUniversity, hospital or other
- Collaborators
- The Second People's Hospital of Foshan, First People's Hospital of Foshan, Maternal and Child Health Hospital of Foshan
- Study start
- 25 Sep 2024 (estimated)
- Primary completion
- 1 Nov 2024 (estimated)
- Study completion
- 1 Dec 2024 (estimated)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.
Detailed description
Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study analyzes data from European populations included in genome-wide association studies (GWAS) from UK Biobank and FinnGen, focusing on individuals with available plasma VEGF family protein levels and placenta previa data.
Key inclusion criteria (1 listed)
- Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.
Key exclusion criteria (1 listed)
- Participants with incomplete or missing data on plasma VEGF levels or placenta previa.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Causal relationship between plasma VEGFA levels and the risk of placenta previa
Time frame: Data analysis and outcome assessment will be completed by December 2024
This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
3 secondary outcomes
Causal relationship between plasma VEGFB levels and the risk of placenta previa
Time frame: Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma VEGFC levels and the risk of placenta previa
Time frame: Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma PLGF levels and the risk of placenta previa
Time frame: Data analysis and outcome assessment will be completed by December 2024
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
- Derived from this study: PubMed 42888602Hong Z, Xu Z, Huang Z, Li W, Liu Q. Causal association between plasma vascular endothelial growth factor family proteins and placenta previa: A 2-sample Mendelian randomization study. Medicine (Baltimore). 2026 Oct 16;105(42):e51193. doi: 10.1097/MD.0000000000051193.
Related trials for Placenta Previa
Not yet recruiting
ERAS Protocol for Cesarean Delivery in Women With Placenta Previa
Placenta Previa
Not yet recruitingObservational study
Placenta-Cervical Interface Angle for Predicting Placenta Accreta Spectrum Severity
Placenta Accreta Spectrum, Placenta Previa
Not yet recruitingObservational study
Hematological and Coagulation Markers in Predicting Placenta Accreta Spectrum in Placenta Previa
Placenta Accreta Spectrum, Placenta Previa
RecruitingObservational study
AI Blind-Sweep Ultrasound for Antenatal Screening by Non-Specialist Health Workers in Rural DR Congo
Antenatal Care, Maternal Health
Recruiting
Effect of a Cervical Pessary on the Rate of Bleeding in Placenta Praevia
Placenta Previa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Previa, run by Guangzhou Institute of Respiratory Disease.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Zhibin Xu (+8615816832640, unignorable_xuzhibin@outlook.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Causal relationship between plasma VEGFA levels and the risk of placenta previa (time frame: Data analysis and outcome assessment will be completed by December 2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06620068, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.